Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung Ju; Yang, James Chih Hsin; Han, Ji Youn; Hochmair, Maximilian; Lee, Ki Hyeong; Delmonte, Angelo; Campelo, M.R. García; Kim, Dong Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander I.; Gettinger, Scott; Tiseo, Marcello; Lin, Huamao Mark; Liu, Yuyin; Vranceanu, Florin; Niu, Huifeng; Zhang, Pingkuan; Popat, Sanjay

doi:10.1016/j.jtho.2021.07.035

Cited by 232 publications

(248 citation statements)

References 21 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“… 9 Similarly, in the ALTA-1L trial, brigatinib demonstrated an OR of 74% compared to 62% with crizotinib and an HR for disease progression or death of 0.48. 17 Acknowledging the limitations of cross-trial comparisons, lorlatinib had a lower HR for disease progression or death of 0.28 relative to alectinib and brigatinib. 11 …”

Section: Systemic Response Of Lorlatinib In Advanced Alk-positive Nsclcmentioning

confidence: 99%

See 1 more Smart Citation

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Yun

Bazhenova

2022

CMAR

View full text Add to dashboard Cite

Lorlatinib is an oral third-generation inhibitor of anaplastic lymphoma kinase (ALK) with activity in advanced ALK-positive non-small cell lung cancer (NSCLC) in both the first and subsequent line setting. Superior systemic and intracranial efficacy of lorlatinib over crizotinib, a first-generation ALK tyrosine kinase inhibitor (TKI), in treatment-naïve patients with advanced ALK-positive NSCLC was demonstrated by the phase 3 CROWN trial. Lorlatinib retains anti-tumor effect against single and some compound ALK resistance mutations after disease progression on first- and second-generation ALK TKIs. Currently, alectinib, brigatinib, ceritinib, crizotinib and lorlatinib are approved for treatment of advanced ALK-positive NSCLC. However, no head-to-head studies have directly compared lorlatinib to second-generation ALK inhibitors. Herein, we aim to provide an overview of the efficacy and safety of lorlatinib and discuss where lorlatinib stands in the therapeutic approach to advanced ALK-positive NSCLC.

show abstract

Section: Systemic Response Of Lorlatinib In Advanced Alk-positive Nsclcmentioning

confidence: 99%

“… 17 Acknowledging the limitations of cross-trial comparisons, lorlatinib had a lower HR for disease progression or death of 0.28 relative to alectinib and brigatinib. 11 …”

Section: Systemic Response Of Lorlatinib In Advanced Alk-positive Nsclcmentioning

confidence: 99%

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Yun

Bazhenova

2022

CMAR

View full text Add to dashboard Cite

show abstract

“…Although OS data were still maturing, posthoc analyses suggested, in patients with baseline brain metastases, an OS benefit for brigatinib (HR, 0.43). 32 …”

Section: Alta-1l Trialmentioning

confidence: 99%

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Rijavec¹,

Biello²,

Indini³

et al. 2022

CPAA

View full text Add to dashboard Cite

Rearrangement of anaplastic lymphoma kinase ( ALK ) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years.

show abstract

“…The median PFS and ORR for patients treated with brigatinib was 24 months and 74%, respectively, compared with 11.1 months and 62% for those treated with crizotinib, respectively. 161 With longer follow‐up, patients with brain metastasis have benefited more from brigatinib treatment compared with crizotinib treatment. 161 In preclinical studies, brigatinib showed potential to overcome the ceritinib‐ or alectinib‐resistance mutations, including G1202R, F1174C/V, and I1171N/T/S.…”

Section: Targeted Therapy For Nsclcmentioning

confidence: 99%

“… 161 With longer follow‐up, patients with brain metastasis have benefited more from brigatinib treatment compared with crizotinib treatment. 161 In preclinical studies, brigatinib showed potential to overcome the ceritinib‐ or alectinib‐resistance mutations, including G1202R, F1174C/V, and I1171N/T/S. 162 …”

Section: Targeted Therapy For Nsclcmentioning

confidence: 99%

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Yuan

Zhang

2021

MedComm

View full text Add to dashboard Cite

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past decades, despite the rapid development of targeted therapy and immunotherapy in non‐small cell lung cancer (NSCLC). The development and availability of comprehensive genomic profiling make the classification of NSCLC more precise and personalized. Most treatment decisions of advanced‐stage NSCLC have been made based on the genetic features and PD‐L1 expression of patients. For the past 2 years, more than 10 therapeutic strategies have been approved as first‐line treatment for certain subgroups of NSCLC. However, some major challenges remain, including drug resistance and low rate of overall survival. Therefore, we discuss and review the therapeutic strategies of NSCLC, and focus on the development of targeted therapy and immunotherapy in advanced‐stage NSCLC. Based on the latest guidelines, we provide an updated summary on the standard treatment for NSCLC. At last, we discussed several potential therapies for NSCLC. The development of new drugs and combination therapies both provide promising therapeutic effects on NSCLC.

show abstract

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Cited by 232 publications

References 21 publications

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Contact Info

Product

Resources

About